140 related articles for article (PubMed ID: 9495620)
1. Decrease of left ventricular mass is a clinically valuable intermediate end-point of antihypertensive treatment.
Agabiti-Rosei E
Blood Press Suppl; 1997; 2():13-5. PubMed ID: 9495620
[TBL] [Abstract][Full Text] [Related]
2. Left ventricular hypertrophy: how to influence an important risk factor in hypertension.
Agabiti-Rosei E; Muiesan ML
J Hypertens Suppl; 1998 Jan; 16(1):S53-8. PubMed ID: 9534098
[TBL] [Abstract][Full Text] [Related]
3. Left ventricular hypertrophy and heart failure in women.
Agabiti-Rosei E; Muiesan ML
J Hypertens Suppl; 2002 May; 20(2):S34-8. PubMed ID: 12183849
[TBL] [Abstract][Full Text] [Related]
4. [Physiopathology of left ventricular hypertrophy].
Waeber B; Weber R; Brunner HR
Arch Mal Coeur Vaiss; 1995 Feb; 88 Spec No 2():9-14. PubMed ID: 7646313
[TBL] [Abstract][Full Text] [Related]
5. From left ventricular hypertrophy to congestive heart failure: management of hypertensive heart disease.
Gradman AH; Alfayoumi F
Prog Cardiovasc Dis; 2006; 48(5):326-41. PubMed ID: 16627048
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of subclinical target organ damage for risk assessment and treatment in the hypertensive patients: left ventricular hypertrophy.
Agabiti-Rosei E; Muiesan ML; Salvetti M
J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S104-8. PubMed ID: 16565230
[TBL] [Abstract][Full Text] [Related]
7. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study.
Okin PM; Devereux RB; Gerdts E; Snapinn SM; Harris KE; Jern S; Kjeldsen SE; Julius S; Edelman JM; Lindholm LH; Dahlöf B;
Circulation; 2006 Mar; 113(12):1588-96. PubMed ID: 16534012
[TBL] [Abstract][Full Text] [Related]
8. Epicardial coronary artery size in hypertensive and physiologic left ventricular hypertrophy.
Kozakova M; Paterni M; Bartolomucci F; Morizzo C; Rossi G; Galetta F; Palombo C
Am J Hypertens; 2007 Mar; 20(3):279-84. PubMed ID: 17324740
[TBL] [Abstract][Full Text] [Related]
9. [Regression of left ventricular hypertrophy in hypertensive heart disease].
Hennersdorf MG; Schannwell CM; Schwartzkopff B; Strauer BE
Herz; 2003 Dec; 28(8):764-78. PubMed ID: 14689112
[TBL] [Abstract][Full Text] [Related]
10. Impact of myocardial diastolic dysfunction on coronary flow reserve in hypertensive patients with left ventricular hypertrophy.
Galderisi M; Cicala S; De Simone L; Caso P; Petrocelli A; Pietropaolo L; Celentano A; Mininni N; de Divitiis O
Ital Heart J; 2001 Sep; 2(9):677-84. PubMed ID: 11666096
[TBL] [Abstract][Full Text] [Related]
11. Effects of four antihypertensive monotherapies on cardiac mass and function in hypertensive patients with left ventricular hypertrophy: randomized prospective study.
Rakić D; Rumboldt Z; Bagatin J; Polić S
Croat Med J; 2002 Dec; 43(6):672-9. PubMed ID: 12476475
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE).
Okin PM; Oikarinen L; Viitasalo M; Toivonen L; Kjeldsen SE; Nieminen MS; Edelman JM; Dahlöf B; Devereux RB;
Circulation; 2009 Apr; 119(14):1883-91. PubMed ID: 19332468
[TBL] [Abstract][Full Text] [Related]
13. [Arrhythmia risk and noninvasive markers in hypertensive left ventricular hypertrophy].
Akdeniz B; Güneri S; Badak O; Aslan O; Tamci B
Anadolu Kardiyol Derg; 2002 Jun; 2(2):121-9; AXVII. PubMed ID: 12134537
[TBL] [Abstract][Full Text] [Related]
14. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
Palmieri V; Devereux RB
Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
[TBL] [Abstract][Full Text] [Related]
15. Hypertension to heart failure: a pathophysiological spectrum relating blood pressure, drug treatments and stroke.
Subramaniam V; Lip GY
Expert Rev Cardiovasc Ther; 2009 Jun; 7(6):703-13. PubMed ID: 19505285
[TBL] [Abstract][Full Text] [Related]
16. [Left ventricular hypertrophy and cardiovascular risk in hypertension].
Amabile G
Ann Cardiol Angeiol (Paris); 1998 Feb; 47(2):86-90. PubMed ID: 9772934
[TBL] [Abstract][Full Text] [Related]
17. Hypertensive heart disease.
Diamond JA; Phillips RA
Hypertens Res; 2005 Mar; 28(3):191-202. PubMed ID: 16097361
[TBL] [Abstract][Full Text] [Related]
18. [Ventricular arrhythmia and sudden cardiac death: the significance of left ventricular hypertrophy as risk factor].
Schmieder RE; Messerli FH
Schweiz Med Wochenschr; 1993 Jan; 123(4):99-107. PubMed ID: 7678943
[TBL] [Abstract][Full Text] [Related]
19. Prevention and reduction of left ventricular hypertrophy in the elderly.
Lavie CJ; Milani RV; Messerli FH
Clin Geriatr Med; 1996 Feb; 12(1):57-68. PubMed ID: 8653663
[TBL] [Abstract][Full Text] [Related]
20. [Cardiac failure in hypertensive cardiopathy].
Verdecchia P
Ital Heart J; 2000 Jun; 1 Suppl 2():72-7. PubMed ID: 10905132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
